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Background—Chemokine signaling through CCR3 is a key regulatory pathway for eosinophil 
recruitment into tissues associated with allergic inflammation and asthma. To date, none of the 
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CCR3 antagonists have shown efficacy in clinical trials. One reason may be their unbiased mode 
of inhibition that prevents receptor internalization, leading to drug tolerance.
Objective—We sought to develop a novel peptide nanoparticle CCR3 inhibitor (R321) with a 
biased mode of inhibition that would block G-protein signaling, but enable or promote receptor 
internalization.
Methods—Self-assembly of R321 peptide into nanoparticles and peptide binding to CCR3 were 
analyzed by dynamic light scattering and NMR. Inhibitory activity on CCR3 signaling was 
assessed in vitro using flow cytometry, confocal microscopy, and western blot analysis in a 
CCR3+ eosinophil cell line and blood eosinophils. In vivo effects of R321 were assessed using a 
triple allergen mouse asthma model.
Results—R321 self-assembles into nanoparticles and binds directly to CCR3, altering receptor 
function. IC50 values for eotaxin-induced chemotaxis of blood eosinophils are in the low 
nanomolar range. R321 inhibits only the early phase of ERK1/2 activation and not the late phase 
generally associated with β-arrestin recruitment and receptor endocytosis, promoting CCR3 
internalization and degradation. In vivo, R321 effectively blocks eosinophil recruitment into the 
lungs and airways and prevents airway hyperresponsiveness in a mouse eosinophilic asthma 
model.
Conclusions—R321 is a potent and selective antagonist of the CCR3 signaling cascade. 
Inhibition through a biased mode of antagonism may hold significant therapeutic promise by 
eluding the formation of drug tolerance.
Graphical Abstract
Keywords
CCR3; eosinophil; allergic inflammation; asthma; biased antagonist; peptide nanoparticles; airway 
hyperresponsiveness
INTRODUCTION
In allergic disorders, such as asthma and eosinophilic esophagitis (EoE), eosinophils are 
recruited into the lung and esophagus, respectively, and activated in excess at these sites of 
inflammation. In these diseases, eosinophils are both a histologic hallmark and among the 
major effector cell types contributing to their pathology1, 2. The C-C chemokine receptor 3 
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(CCR3) signaling pathway is one of the key regulatory pathways involved in eosinophil 
recruitment and migration into the affected tissues as part of the allergic diathesis.
While CCR3 is most highly expressed by eosinophils, it is also expressed by basophils, 
subsets of mast cells and Th2 cells, and airway epithelial cells3–5. CCR3 is a promiscuous 
G-protein-coupled receptor (GPCR), interacting with multiple inflammatory chemokines, 
including the high affinity agonists eotaxin-1 (CCL11), eotaxin-2 (CCL24), eotaxin-3 
(CCL26), and RANTES (CCL5). The receptor is coupled to the pertussis toxin-sensitive G 
protein Gαi. Upon ligand binding, the receptor is activated and active GTP-bound Gαi and 
the Gβγ dimer dissociate from CCR3 to trigger downstream signaling cascades including 
the MAPK (ERK1/2, p38) and the PI3K/AKT pathways6, 7. These intracellular signaling 
pathways culminate in priming, chemotaxis, activation, and degranulation of eosinophils. 
Following receptor activation by the ligand, CCR3 is desensitized and internalized8, 9. The 
mechanism of CCR3 internalization is not yet fully understood, but is thought to occur via 
β-arrestin recruitment to phosphorylated CCR3 and sequestration of the receptor into 
endosomes10. In addition, eotaxin-induced CCR3 internalization may be required for actin 
polymerization and chemotaxis9.
The importance of CCR3 as a potential therapeutic target was established through the 
observations that CCR3-null mice and eotaxin-1 and eotaxin-2 double knockout mice 
displayed near complete abolishment (up to ~70%) of allergen-induced airway eosinophil 
recruitment11. CCR3 transcript and protein levels are increased in the bronchial mucosa of 
patients with allergic asthma12. In line with this, much effort has been invested in the 
development of small molecule CCR3 antagonists, yet none have been approved for clinical 
use to date4.
Most of the currently known CCR3 antagonists are competitive or allosteric inhibitors of 
CCR3 activation and internalization by chemokines4. The dual inhibitory activity of these 
molecules classifies them as unbiased antagonists. Reports on the use of unbiased 
antagonists of other GPCRs, such as CXCR4, suggest that after prolonged exposure, cell 
surface GPCR accumulates, a phenomenon associated with developing resistance to receptor 
inhibition13, 14. These findings prompted us to search for antagonists that can “bias” 
downstream signaling by selectively inhibiting only one of the signaling cascades. There is a 
growing interest in the development of biased agonists of GPCRs,15 but biased antagonists 
of GPCRs remain largely unexplored, very few have been identified, and their therapeutic 
potential remains to be determined.
In the present study, we report the development and validation of R321, a novel peptide 
inhibitor derived from the second transmembrane helix of CCR3. R321 self-assembles into 
uniform nanoparticles and inhibits CCR3-mediated chemotaxis of human blood eosinophils 
with nanomolar potencies. Intravenously administered R321 significantly reduces eosinophil 
recruitment into the lung and airspaces and diminishes airway hyperresponsiveness (AHR) 
in a triple allergen (DRA) mouse asthma model of allergic airway inflammation. We propose 
that the R321 peptide exerts its receptor inhibitory effects on eosinophil function as a biased 
antagonist by inhibiting G-protein mediated processes and promoting the internalization 
(endocytosis) and degradation of CCR3.
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Small molecule CCR3 antagonists, SB238437 and UCB35625, were purchased from Tocris 
Bioscience (Bristol, UK).
Peptide synthesis and characterization
Synthesis, purification and evaluation of nanoparticle formation of R321 and R323 peptides 
were performed as described in the Supplementary Materials.
Cell culture
AML14.3D10-CCR3 cells, an eosinophil-differentiated acute myeloid leukemia cell line 
stably transfected to express CCR3 (ATCC® CRL-12079), were cultured as previously 
described.16 Jurkat cells, a T cell leukemia line endogenously expressing CXCR4, but not 
CCR3, were cultured in RPMI-1640 supplemented with 10% FBS, 1% Penicillin-
streptomycin, and 2 mM L-Glutamine.
Eosinophil purification
Eosinophils were purified from blood drawn from mild allergic asthmatic subjects. 
Peripheral blood was separated over a gradient of Ficoll-Paque Plus (GE Healthcare, 
Pittsburg, PA). Eosinophils were further purified by negative selection using a commercial 
Eosinophil Isolation kit (MAC Miltenyi Biotec, Auburn, CA).
Chemotaxis and degranulation assays
Chemotaxis and degranulation assays are described in the Supplementary Materials.
Prolonged exposure to inhibitors
AML14.3D10-CCR3 cells or human peripheral blood eosinophils were incubated for 24, 48, 
or 72 hours with either vehicle control or 1 μM inhibitors. Cells were resuspended in fresh 
complete medium with inhibitors every day.
Signal transduction – western blotting and confocal microscopy
Detailed descriptions are provided in the Supplementary Materials.
Receptor expression and internalization
To evaluate CCR3 cell surface expression and ligand-induced internalization, cells were 
treated for 30 min with vehicle control, R321 (0.01–10 μM) ± CCL11 (12 nM), or R323, 
SB238437, UCB35625 (all at 1μM) ± CCL11 (12nM). Cells were blocked with 10% heat-
inactivated human AB-serum, stained using PE-conjugated anti-human CCR3 antibody 
(clone 5E8, BioLegend, San Diego, CA) or PE-conjugated isotype-matched control 
(BioLegend, San Diego, CA) and analyzed on a Quanta SC flow cytometer (Beckman 
Coulter, Indianapolis, IN). Cell surface staining and gating strategy employed for the 
enumeration of mouse blood eosinophils and determination of CCR3 surface expression 
levels is described in the Supplementary Materials.
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Female BALB/cJ mice (10–12 weeks of age) were purchased from The Jackson Laboratory 
(Bar Harbor, ME). All animal study protocols were reviewed and approved by the 
Institutional Animal Care and Use Committee of the University of Illinois (Chicago, IL).
Sensitization and airway challenge
Sensitization and intranasal challenges were performed according to the acute asthma 
protocol previously described by Goplen at al17. In brief, mice were sensitized twice ip with 
a cocktail of 3 allergens: Dust-mite (D. Farinae) – 5 μg, ragweed (A. artemisifolia) – 50 μg, 
and Aspergillus fumigatus – 5 μg. All extracts were purchased from Greer Laboratories 
(Lenoir, NC). One week after the second sensitization, intranasal challenges consisting of 
0.15 μg of Aspergillus, 0.15 μg of dust-mite, and 1.5 μg of ragweed extract were given for 3 
consecutive days. Control mice were sham-challenged with PBS. For the prophylactic 
protocol, R321, scrambled R323 peptide control, vehicle, or PBS was delivered by iv 
injection into the retro-orbital sinus one day before the first challenge and directly prior to 
each subsequent challenge. For the therapeutic protocol, mice started receiving 12 mg/kg of 
R321 or R323 on the day after the final allergen challenge and for 3 additional days 
following the date of the last challenge.
Bronchoalveolar lavage, lung histology and airway responsiveness to methacholine
Bronchoalveolar lavage (BAL) was performed as described in the Supplementary Materials. 
Whole lungs were fixed in 10% formalin and embedded in paraffin. Lung tissue sections 
were stained with rat anti-mouse MBP1 antibody (generously provided by the Lee 
laboratories, Mayo Clinic, Scottsdale, AZ) as previously described.18 Immunostained slides 
were scanned using Aperio Scanscope CS2 scanner (Aperio, Vista, CA) and analyzed with 
Aperio's image viewer software. Nuclei were counterstained with Mayer’s Hematoxylin and 
cell counts were expressed as percent of MBP1 positive cells of the total nucleated cell 
count. Determination of airway responsiveness to methacholine is described in the 
Supplementary materials.
NMR
NMR was performed as described in the Supplementary Materials.
Statistical Analysis
Statistical analysis was performed using two-tailed t-tests, one way or two-way ANOVA, 
followed by Tukey post hoc analysis in GraphPad Prism software (GraphPad, San Diego, 
CA).
RESULTS
R321 self-assembles into nanoparticles
Peptides containing sequences from each of the seven transmembrane domains and 
associated extracellular loops of human CCR3 were first screened for inhibition of 
chemotaxis to CCL11, identifying the second transmembrane domain and first extracellular 
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loop region as the most inhibitory (data not shown). The final design of R321 (Fig. 1A) was 
based on a previously described self-assembling CXCR4 peptide antagonist19, 20. Twenty-
seven units of polyethylene glycol (PEG) were placed on the C-terminus of the peptide to 
prevent aggregation, and the PEG units were followed by three aspartate residues that ensure 
homogeneous self-assembly and correct orientation upon membrane fusion (Fig. 1A). The 
control peptide, R323, was derived by randomly, but separately, scrambling the sequences of 
the R321 transmembrane and extracellular loop regions (Fig. 1A). DLS analysis (Fig. 1B) 
showed that R321 and R323 monomers both self-assemble in an aqueous environment into 
nanospheres with a hydrodynamic radius of 7.1± 0.7 nm and 4.5 ± 0.4 nm, respectively, with 
R323 smaller and more polydisperse than R321. The size of the R321 particles was 
maintained over a wide range of monomeric concentrations (Fig. 1C).
R321 specifically inhibits eotaxin-induced eosinophil chemotaxis
Human blood eosinophils and the stable CCR3+ eosinophilic myelocyte cell line, 
AML14.3D10-CCR3, undergo CCR3-mediated chemotaxis induced by multiple chemokines 
including CCL11/eotaxin-1, CCL24/eotaxin-2, and CCL26/eotaxin-3 (Fig. 2). R321 was 
observed to inhibit eotaxin-induced chemotaxis by both primary eosinophils (Fig. 2A) and 
the AML14.3D10-CCR3 cell line (Fig. 2B) in a dose-dependent manner and with nanomolar 
potencies. The IC50 and IC90 values are shown in Fig. 2C. When used at a concentration of 1 
μM (approximate IC90 value for R321), the scrambled peptide control (R323) failed to 
significantly inhibit eotaxin-mediated chemotaxis in blood eosinophils (Fig. 2D). R321 
failed to inhibit CXCR4-mediated chemotaxis in Jurkat T-cells (Fig. 2E) and platelet-
activating factor (PAF)-mediated chemotaxis of blood eosinophils (Supplementary Fig. S1), 
demonstrating the specificity of R321 inhibition of CCR3. Although CCR3 ligands induce 
degranulation of cytochalasin-B treated human eosinophils,21 R321 did not promote CCL11-
induced degranulation and secretion of eosinophil cationic protein (ECP) in blood 
eosinophils (Supplementary Fig. S2).
Effects of R321 on CCR3 signal transduction pathways
R321 was found to inhibit the activation of Gαi in an immunoprecipitation assay that detects 
Gαi-GTP (Fig. 3A) but did not inhibit receptor degradation (Fig. 3B). Pretreatment of 
AML14.3D10-CCR3 cells with 10 μM R321 (a concentration exceeding IC50 and IC90 for 
chemotaxis) before exposure to ligands was even found to enhance degradation of the CCR3 
receptor (Fig. 3B). Both G-protein and β-arrestin mediated signaling pathways can lead to 
AKT and ERK 1/2 activation, although the time course of activation through the two 
pathways is different, leading to biphasic phosphorylation.22–25 Following stimulation of 
AML14.3D10-CCR3 cells with chemokines, biphasic phosphorylation of AKT (Fig. 3C) 
and ERK 1/2 (Fig. 4A) was observed in western blots. The early (2–5min) phosphorylation 
is mediated by G-protein signaling. The late sustained phase (30 min) phosphorylation is 
likely due to β-arrestin signaling as demonstrated for other GPCRs.22, 25, 26 Pretreatment of 
cells for 30 min with 10 μM R321 prior to stimulation lead to a complete inhibition of the 
early phase of ERK 1/2 activation (5 min) but had no effect on the prolonged late phase (30 
min). The control peptide, R323, had no effect on ERK1/2 phosphorylation patterns. Both 
SB328437 and UCB35625 fully inhibited the late phase, with SB328437 blocking the early 
phase as well, and UCB35625 doing so only partially (Fig. 4A). These results indicate that, 
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unlike SB328437 and UCB35625, R321 does not inhibit the β-arrestin signaling that 
mediates the late phase phosphorylation of ERK1/2.
R321 does not antagonize β-arrestin recruitment to CCR3
Co-localization of CCR3 and β-arrestin 2 was observed following stimulation of CCR3 with 
CCL11 (Fig. 4B), suggesting that β-arrestin plays a role in ligand-induced CCR3 
internalization and degradation. Pretreatment of cells with 10 μM R321 or R323 did not 
significantly (p>0.05) alter the reported co-localization coefficients either before or after 
CCL11 stimulation (Fig. 4C). In contrast, co-localization of CCR3 and β-arrestin 2 was 
significantly attenuated after treatment with UCB35625 and SB328437 when compared to 
untreated cells (p≤0.0001) (Fig. 4C). Representative images of antibody controls can be 
found in Supplementary Fig. S3.
R321 promotes rather than inhibits CCR3 internalization and degradation
Inhibition of β-arrestin signaling may interfere with effective degradation of CCR3 and lead 
to receptor accumulation on the eosinophil cell surface. To elucidate the fate of CCR3 upon 
ligand and inhibitor treatment, surface levels of CCR3 in AML14.3D10-CCR3 cells were 
determined by flow cytometry. More than 50% of CCR3 present on the cell surface was 
internalized following 30 min of CCL11 exposure, in keeping with previous reports8, 27. 
R321 and the scrambled R321 peptide control showed no significant effect on ligand-
induced receptor internalization, whereas the small molecule antagonists, UCB35625 and 
SB328437, partially blocked CCR3 internalization and degradation (Fig. 5A). Of note, R321 
at 10 μM was found to promote CCR3 internalization on its own, without the addition of 
chemokine ligand (Fig. 5B).
R321 maintains its efficacy over 72h in contrast to unbiased antagonists
The effects of prolonged exposure to inhibitors on CCL11-induced chemotaxis and CCR3 
surface expression was assessed for up to 72h in AML14.3D10-CCR3 cells and in blood 
eosinophils (Fig. 5C and 5D). CCL11 (12 nM) alone and CCL11 + R321 reduced CCR3 
expression to ~68% and ~55%, respectively, after 24h, and to ~18% and ~12% after 72h 
(Fig. 5D). Treatment of cells for 72h with R321 alone reduced surface levels of CCR3 to 
68%, as compared to untreated cells. In contrast, UCB35625 lead to receptor accumulation 
on the surface and enhanced CCR3 surface levels up to 133% after 72h. R323 and 
SB328437 had no significant effect on receptor levels. A similar effect was observed on 
CCR3 surface expression in AML14.3D10-CCR3 cells (Supplementary Fig. S4). In 
agreement with the levels of CCR3 expression detected, R321 did not lose any of its 
inhibitory potency during 72h of treatment (maintaining 90% inhibition of chemotaxis), 
while UCB35625 and SB328437 inhibition levels dropped by 19.3% and 13.7%, 
respectively (Fig. 5C). These results indicate that resistance to the small molecule inhibitors, 
but not to R321, develops over time.
R321 inhibits eosinophil recruitment into the lung and airspaces
In a robust mouse DRA allergic asthma model of eosinophilic airway inflammation (Fig. 
6A), prophylactically (Supplementary Fig. S5A) administered iv R321 demonstrated a dose-
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dependent inhibitory effect on eosinophil recruitment into the airways (Fig. 6B). 
Significantly, R321 reduced eosinophil counts in the BALF beginning with a dose of 6 
mg/kg (44.24 ± 9.33 % of vehicle) and reached 69.33 ± 4.20% inhibition at the maximum 
dose of 12 mg/kg (Fig. 6C). An IC50 value of 8.16 mg/kg was obtained from linear 
regression analysis. R323 showed no inhibitory effect at 12 mg/kg. No significant 
differences were observed in total cell counts of other inflammatory cells including 
macrophages, neutrophils, or lymphocytes (Supplementary Fig. S6). MBP1-stained lung 
tissues showed a 36.20 ± 5.28% decrease in eosinophil counts following treatment with 12 
mg/kg of R321 (Fig. 6D). In a therapeutic protocol (Supplementary Fig. S5B), R321 (12 
mg/kg) successfully reduced airway (BAL) eosinophils by 74.18 ± 6.50%. (Fig. 7A) and 
lung eosinophils by 83.30 ± 7.29 %, fully reversing both allergen-induced eosinophilia in the 
blood (Fig. 7B) and in the lung tissue (Fig. 7C and 7E) to levels comparable to PBS-sham 
challenged mice. As expected, blood eosinophils displayed reduced levels of surface CCR3 
upon exposure to allergen when compared to sham-challenged controls (~29% reduction) 
(Fig. 7D), and R321 treatment further reduced CCR3 levels (~15% reduction compared to 
vehicle, p=0.01). The protocols for allergen (DRA) sensitization, airway challenge, and 
peptide treatments are provided in Supplemental Fig. S5.
R321 blocks airway hyperresponsiveness in allergen-challenged mice
DRA-challenged mice showed a ~9 times higher peak system and airway resistance in 
response to methacholine as compared to sham-challenged (PBS) mice (Fig. 6E and Fig. 
6F). R321 treatment had a striking effect on airway responsiveness, reducing both the 
system and airway pulmonary resistance of challenged mice to levels comparable to those 
observed in sham-challenged (PBS) mice.
R321 interacts with CCR3 and allows chemokine binding
To study the binding of R321 to CCR3, we used NMR spectroscopy to correlate 13C and 1H 
frequencies in 13CH3 groups of membrane proteins incorporated by reductive methylation 
(Supplementary Fig. S7) 28–33. The HSQC spectrum of CCR3 positive membranes 
contained four discernable signals (Fig. 7A). In contrast, CCR3 null membrane exhibited 
only two signals (Fig. 7A). These signals overlapped with only two out of four signals of 
CCR3 positive membranes, suggesting that the remaining two signals belong to CCR3 (Fig. 
7A). Immunoblotting only detected CCR3 in the CCR3 positive membranes (Supplementary 
Fig. S8). Moreover, CCL11 specifically reduced the intensity of CCR3 signals (Fig. 7B, 
black arrows) but did not affect the spectrum of CCR3 null membranes (Supplementary Fig. 
S8). Similar to CCL11, R321 shifted only the CCR3 signals (Fig. 7C). This suggests that 
R321 specifically perturbs CCR3 structure. Next, we investigated the interaction of R321 
and CCR3 in the presence of CCL11 (Fig. 7D–F). The chemical shift changes and 
differences in signal intensities show that neither CCL11 nor R321 interfere with each 
other’s binding to the receptor. This suggests that R321 and CCL11 interact with CCR3 
simultaneously and R321 alters CCL11’s ability to activate signaling (Fig. 7).
Dose-dependent responses of CCR3 at different concentrations of R321 (Supplementary Fig. 
S7 and Fig. S9) allowed calculation of the dissociation constants (Supplementary Fig. S7C). 
We found two dissociation constants for R321 binding to the receptor, one in the nanomolar 
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range and the other in the micromolar range. This suggests that R321 might employ two 
distinct mechanisms for interaction with CCR3, potentially explaining its unique inhibitory 
profiles in vitro and in vivo.
DISCUSSION
In the present study, we report the development and characterization of a novel peptide 
inhibitor of CCR3. The described peptide (R321) self-assembles into uniformly sized 
nanoparticles, essentially functioning as its own carrier and delivery system. Self-assembly 
protects the peptide from proteolytic degradation, a known issue with peptide-based drugs20. 
Addition of polyethylene glycol (PEG) to the R321 nanoparticles is recognized to further 
prevent aggregation, proteolytic degradation, improve pharmacokinetics, and reduce 
immunogenicity of peptide based drugs34.
In this study, iv administration was used as the most reliable method for delivering R321 
peptide nanoparticles to the systemic circulation. However, future studies will involve 
alternative routes of administration, notably formulating R321 preparations for nebulization 
or direct airway instillation or inhalation. UCB35625, initially identified as a high affinity 
unbiased antagonist of CCR3 and CCR1, was subsequently found to be an agonist of CCR2 
and CCR5, making it prohibitively complex for in vivo studies35, 36. SB328437 was 
developed as a specific inhibitor of CCR3 in eosinophils and was shown to successfully 
suppress OVA-induced accumulation of eosinophils in the lungs of mice adoptively 
transferred with in vitro-differentiated Th2 cells37, 38. However, a very high subcutaneous 
dose (100 mg/kg) of SB328437 resuspended with Tween-80 was used in the study, and we 
have also experienced solubility issues with this compound, making it unsuitable for iv 
injection.
CCR3 signaling is increasingly implicated in various pathological contexts besides allergic 
inflammation. These include age-related macular degeneration,39 reproductive malignancies,
40–42 eosinophilic myocarditis,43 neurodegenerative diseases,44 renal cell carcinoma,45 
Crohn’s disease,46 and glioblastoma.47 Several antagonists that prevent chemokine binding 
to CCR3 have been developed; however, none of these inhibitors have been FDA approved. 
Failures of small molecule CCR3 inhibitors in the few clinical trials that have been 
conducted have called into question the role of CCR3 in airway eosinophilia in asthma, 
suggesting that CCR3 is not a viable target for drug development. However, a clinical trial of 
the unbiased CCR3 antagonist, GW766994, showed a trend towards inhibition of sputum 
eosinophils, with significant inhibition of AHR,48 suggesting treatment duration may not 
have been sufficient to meet primary study endpoints,48, 49 or eosinophils and other CCR3+ 
target cells developed resistance (tolerance) to this unbiased antagonist. Furthermore, studies 
have shown that CCR3 knock-out mice display up to a maximum of 70% reduction in 
eosinophil recruitment into the airways in an OVA-asthma model.50 In agreement with this 
finding, our in vivo results from the mouse DRA-asthma model also validate CCR3 as a 
drug target, since the highest prophylactically administered dose of R321 reached ~70% 
inhibition of eosinophil recruitment into the airways and strikingly, when delivered 
therapeutically, completely reversed both blood and lung tissue allergen-induced 
eosinophilia. The inhibitory effect on blood eosinophil numbers could be explained by either 
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R321 blocking egress of eosinophils from the bone marrow and/or decreasing eosinophil 
differentiation.51 Further studies are warranted, including in severe chronic murine asthma 
models. Despite incompletely inhibiting eosinophil recruitment to the airways, R321 
delivered at 12 mg/kg fully blocked the development of AHR to methacholine in allergen-
challenged mice. Airway hyperresponsiveness is considered a cardinal feature of asthma, 
and the ability of R321 to completely antagonize the development of AHR in a robust 
allergic asthma model offers promise of R321 as a therapeutic agent in the treatment of the 
eosinophilic asthma phenotype. The presence of CCR3 on other non-eosinophil cells 
relevant to asthma and airway hyperreactivity, such as basophils and subsets of mast cells 
and Th2-lymphocytes could indicate a wider therapeutic effect of R321 beyond inhibition of 
eosinophil recruitment and activation.
Drug development thus far has focused on conventional unbiased antagonists, despite 
growing evidence that chemokine receptors mediate effects both through G protein and non-
G protein effectors. An unbiased antagonist of CCR3 acts to inhibit both the activation 
branch as well as the desensitization and degradation branch of CCR3 signaling following 
ligand binding. In this scenario, the cell increases its surface receptor density as the basal 
turnover process continues to produce new receptors.52, 53 Receptor accumulation may 
potentially explain the limited in vivo success observed with such unbiased antagonists, e.g. 
in a clinical trial in subjects with eosinophilic asthma,48 as eosinophils may eventually 
overcome inhibition and become resistant.
Our results demonstrate that the novel R321 peptide effectively inhibits G-protein mediated 
signal transduction by CCR3, but does not interfere with β-arrestin signaling, receptor 
internalization and degradation (Supplemental Figure S10). In contrast, small molecule 
CCR3 antagonists, UCB35625 and SB328437, partially or completely block CCR3 
internalization, with this effect becoming more pronounced with longer treatment times. Our 
observation that R321 by itself appears to promote CCR3 internalization, and without acting 
as an agonist for chemotaxis, suggests the fate of CCR3 internalized in the presence of R321 
is biased towards that of degradation instead of cell activation. As demonstrated by NMR 
studies, both R321 and CCL11 can bind simultaneously and specifically to the CCR3 
receptor, and R321 has two independent binding sites. It is possible that R321 binding at a 
site different than the eotaxin ligand stabilizes a receptor conformation that induces β-
arrestin recruitment, although with a much weaker affinity than observed for the eotaxin 
ligands. Future structural studies should help clarify the unique inhibitory profile of R321.
Avoiding the pitfall of tolerance development by seeking out novel biased antagonists of the 
CCR3 signaling cascade may hold significant therapeutic promise for eosinophilic asthma, 
EoE and other eosinophil-associated diseases. Our results should also prove encouraging in 
a continuing search for biased antagonists of not only CCR3, but also other chemokine 
receptors, and point the way toward approaches alternative to classical ligand-displacement 
compounds.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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AHR Airway Hyperresponsiveness
BALF Bronchoalveolar lavage fluid
CCR3 C-C chemokine receptor 3
DRA Dust mite, Ragweed, and Aspergillus
DLS dynamic light scattering
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EoE Eosinophilic Esophagitis
GPCR G-protein-coupled receptor
NMR Nuclear Magnetic Resonance
PAF platelet-activating factor
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• R321 is a novel biased nanoparticle CCR3 antagonist that inhibits G-protein 
signaling but not β-arrestin-mediated CCR3 internalization and degradation
• R321 blocks eosinophil recruitment into the blood, lungs and airways and 
prevents airway hyperresponsiveness in a mouse eosinophilic asthma model
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Figure 1. The R321 CCR3 peptide and its scrambled control (R323) self-assemble into 
nanoparticles
(A) Structures of R321 and the scrambled peptide R323. Alignment with human and mouse 
CCR3 shows a high degree of identity at the TM2 region. (B) Dynamic Light Scattering 
(DLS) regularization distribution histograms are shown for 10 μM peptide solutions in PBS. 
Radii for R321 and R323 are 7.1 ± 0.7 nm and 4.5 ± 0.4 nm, respectively, with R323 
somewhat smaller and more polydisperse; the polydispersity index of R321 and R323 were 
0.07 and 0.28, respectively. Results represent mean ± SEM from experiments (n=3) 
performed in duplicate (C). R321 self-assembly into nanoparticles shows no dependence on 
peptide concentration. TM: transmembrane. ECL: extracellular loop.
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Figure 2. R321 inhibits eotaxin/CCR3-mediated chemotaxis
R321 (0.001–10 μM) dose-response inhibition of chemotaxis induced by CCL11/Eotaxin-1 
(12nM), CCL24/Eotaxin-2 (20nM), and CCL26/Eotaxin-3 (100nM) for 4h of (A) blood 
eosinophils and (B) AML14.3D10-CCR3 cells. (C) IC50/IC90 inhibitory activity of the R321 
peptide on eotaxin-induced chemotaxis of blood eosinophils. (D) Scrambled peptide control 
– R323 (1 μM) does not significantly inhibit chemotaxis of blood eosinophils. In contrast, 
R321 inhibits chemotaxis by >90% when tested at the same (1 μM) concentration. (E) R321 
does not inhibit CXCL12/CXCR4-mediated chemotaxis of Jurkat-T lymphocytic leukemia 
cells. Results are normalized to % maximum chemotactic response and are representative of 
the mean ± SEM from experiments (n=3) performed in triplicate. ns=p>0.05.
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(A) R321 inhibits activation of pertussis toxin (PT) sensitive Gαi. AML14.3D10-CCR3 
cells were pretreated with PT (200 ng/mL) or R321 (10 μM) before being stimulated with 
CCL11 (12 nM) for 1 min. Active, GTP-bound Gαi was immunoprecipitated using antibody 
specific for GαiGTP and detected by western blotting using antibody to total Gαi. The input 
lysates were blotted for CCR3 as a loading control. (B) R321 does not inhibit β-arrestin 
signaling by activated CCR3. AML14.3D10-CCR3 cells were treated with CCL11 (12 
nM) or RANTES/CCL5 (12 nM) for 3h. Decrease in CCR3 indicates receptor degradation 
after exposure to ligand. Pretreatment with 10 μM R321 before CCR3 ligands enhances 
degradation. (C) Eotaxin-mediated activation of CCR3 leads to biphasic activation of 
AKT. After CCR3 activation by the indicated chemokines (12 nM), biphasic 
phosphorylation of AKT was observed. Acute (2min) phosphorylation is mediated by G 
protein signaling. Late phase (30min) phosphorylation is likely due to β-arrestin signaling.
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Figure 4. R321 does not inhibit ligand-induced β-arrestin recruitment and signaling by activated 
CCR3
(A) Following CCR3 activation with 100 nM CCL11, biphasic ERK1/2 phosphorylation was 
observed. Acute (2–5min) phosphorylation is mediated by G protein signaling. Late phase 
(30min) phosphorylation is likely due to β-arrestin signaling. R321 (10μM) inhibits only 
acute phosphorylation of ERK1/2. Scrambled peptide control – R323 (10μM) does not 
inhibit acute or late phase phosphorylation. SB328437 (10μM) inhibits both acute and late 
phase phosphorylation and UCB35625 (10μM) inhibits the late phase to a higher degree than 
the early phase. (B) Representative confocal images of AML14.3D10-CCR3 cells exposed 
to vehicle or inhibitors for 30 min and stimulated with CCL11/eotaxin-1 for 30 min. (C) 
Quantitation by Pearson’s correlation method shows colocalization of CCR3 to β-arrestin2 
30 min after stimulation with CCL11/eotaxin-1. R321 and R323 (10 μM) did not inhibit 
CCL11-induced β-arrestin2 recruitment to CCR3 whereas the CCR3 antagonist SB328437 
and UCB35625 strongly inhibited colocalization. Results represent mean (50 cells per 
treatment group) ± SEM from 3 independent experiments. (*p ≤ 0.05, **p≤ 0.01,****p ≤ 
0.0001 as compared to control).
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Figure 5. R321 does not inhibit CCL11-induced CCR3 internalization and does not induce 
resistance (tolerance) to inhibition of CCL11-induced chemotaxis
(A) R321 does not inhibit CCL11-mediated internalization of CCR3. When added 
concurrently with 12 nM CCL11, R321 (1μM) and R323 (1μM) did not interfere with 
CCL11-induced receptor internalization. Both SB328437 (1 μM) and UCB35625 (1 μM) 
significantly inhibited the chemokine’s ability to induce CCR3 internalization. (B) R321 
alone decreases CCR3 surface expression. R321 dose-response reduction of surface CCR3 
expression on AML14.3D10-CCR3 cells. Significant internalization levels were reached at 
1μM R321. (C) R321 maintains prolonged inhibitory activity. AML14.3D10-CCR3 cells 
were treated for 24h, 48h or 72h with R321 or unbiased antagonists (all at 1 μM) ± CCL11 
(12 nM). (D) R321 promotes CCR3 internalization in human blood eosinophils over a 
prolonged incubation period. Results shown as surface expression of CCR3 as percentage of 
vehicle expression. Of note, SB328437, when used at equimolar concentrations to R321 and 
UCB35625 (1μM), was a less effective inhibitor of CCL11/CCR3-mediated chemotaxis and 
failed to promote CCR3 cell surface accumulation. Results represent mean ± SEM from 
experiments (n=3) performed in triplicate. Compared to vehicle (B, D) or 24h data point (C): 
*p ≤ 0.05, **p ≤ 0.01, ***p<0.001, ****p ≤ 0.0001; Error bars = SEM.
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Figure 6. Prophylactic treatment with R321 significantly reduces eosinophil recruitment into the 
lung airspaces
(A) The DRA-allergen challenge induces a robust eosinophilic response in female BALB/cJ 
mice as demonstrated by increased numbers of eosinophils in the BAL fluid. (B) Total 
eosinophil cell numbers (x10 ) in the BAL fluid show that R321 significantly inhibits 
eosinophil recruitment into the lung airspaces starting at an iv dose of 6 mg/kg. (C) The 
inhibitory effect of R321 is dose-dependent and reaches 69.33 ± 4.20% inhibition at 12 
mg/kg. (D) Lungs were stained with anti-mMBP1 antibody to identify eosinophils. R321 (12 
mg/kg) treatment reduces lung tissue eosinophil counts by 36.20 ± 5.28%. Results are 
displayed as % of mMBP1 positive cells as compared to total nucleated cells. The mean ± 
SEM are shown for 6–7 mice/treatment group from 3 independent experiments. R321 at 12 
mg/kg significantly lowers respiratory system (E) and airway (F) responsiveness to 
methacholine as compared to vehicle or R323 controls. There is no significant difference 
between R321 treated and sham-challenged mice (n=5, except PBS group where n=4). 
(****p<0.0001, ***p<0.001,**p<0.01, *p<0.05, ns not significant).
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Figure 7. Therapeutic treatment with R321 attenuates established asthmatic lung and airway 
inflammation in allergen-sensitized/challenged mice
(A) R321 administered at 12 mg/kg inhibits recruitment of eosinophils to the lung airspaces 
by 74.18 ± 6.50%. (B) DRA-allergen challenged mice (Vh) develop significant blood 
eosinophilia as compared to sham-challenged mice (PBS). Treatment with R321 reduces 
blood eosinophil numbers to levels not significantly different than those observed in allergen 
sensitized/PBS-sham challenged mice. (C) Following therapeutic treatment with 12 mg/kg 
of R321, lungs stained for MBP1 positive cells showed tissue eosinophil counts not 
significantly different from the PBS-sham challenged mice, an 83.30 ± 7.29 % reduction 
compared to vehicle control. Results are expressed as % MBP1 positive cells compared to 
total nucleated cells. (D) Surface expression of CCR3 in blood eosinophils is reduced upon 
allergen challenge. R321 does not inhibit CCR3 internalization, but has a promoting effect 
(vehicle MFI of 13.7 vs. R321-treated group MFI of 11.7, p=0.01). The mean ± SEM is 
shown for 5 mice/treatment group. (****p<0.0001, ***p<0.001,**p<0.01, *p <0.05,ns not 
significant). (E) Representative images of mouse lung airways (top) and blood vessels 
(bottom) from Fig. 7C immunostained with HRP-conjugated antibodies to MBP1 (positive 
cells are dark brown). Black bars represent 100 μm.
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Figure 8. R321 binds CCR3 in plasma membrane in the presence of CCL11
13C HSQC spectra of 13C-reductively methylated CCR3 positive and CCR3 null membranes 
were recorded with/without 1 μM CCL11 in the presence/absence of 2 μM R321. Spectral 
comparisons between (A) CCR3 (CCR3-K-di13CH3)(red) and CCR3 null membranes (blue); 
(B) CCR3 alone (CCR3-K-di13CH3) (red) and CCR3 + CCL11 (blue); (C) CCR3 alone 
(CCR3-K-di13CH3) (red) and CCR3 + R321 (blue); (D) CCR3 alone (CCR3-K-di13CH3) 
(red) and CCR3 + CCL11 and R321 (blue); (E) CCR3 + CCL11 (red) and CCR3 + CCL11 
and R321 (blue); and (F) CCR3 + R321 (red) and CCR3 + CCL11 and R321 (blue) show 
line-broadening and chemical shift changes indicative of binding. Black arrows show 
significant changes in CCR3-associated signals, but not in the signals that belong to other 
membrane proteins.
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